ciglitazone has been researched along with Bright Disease in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panzer, U | 1 |
| Zahner, G | 1 |
| Wienberg, U | 1 |
| Steinmetz, OM | 1 |
| Peters, A | 1 |
| Turner, JE | 1 |
| Paust, HJ | 1 |
| Wolf, G | 1 |
| Stahl, RA | 1 |
| Schneider, A | 1 |
1 other study available for ciglitazone and Bright Disease
| Article | Year |
|---|---|
15-deoxy-Delta12,14-prostaglandin J2 inhibits INF-gamma-induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells.
Topics: Animals; Cells, Cultured; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chromans; Gene Expres | 2008 |